- (anti-IFN-aR)
nirsevimab (anti-RSV)
MedImmune, Inc. v. Genentech, Inc. "12
years on,
Astra draws a line
under Medimmune". Evaluate.com. 2019-02-14. Retrieved...
-
Cambridge Antibody Technology (in 2006),
MedImmune (in 2007),
Spirogen (in 2013) and
Definiens (by
MedImmune in 2014). It has its
research and development...
-
Tetra in the
European Union.
FluMist was
first introduced in 2003 by
MedImmune. In the
United States,
FluMist is
approved for self- or caregiver-administration...
-
MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007), was a
decision by the
Supreme Court of the
United States involving patent law. It
arose from...
-
patents cover Medimmune's processes for
generating the
collections of
human antibody genes that
comprise MedImmune Cambridge libraries.
MedImmune has patents...
-
actual controversy was most
recently addressed by the
Supreme Court in
MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007). But even if an
actual controversy...
-
center for biotechnology.
Prominent local biotechnology companies include MedImmune,
United Therapeutics, The
Institute for
Genomic Research,
Human Genome...
- company, the J.
Craig Venter Institute (JCVI), and
AstraZeneca (formerly
MedImmune).
Maryland is home to
defense contractor Emergent BioSolutions, which...
-
alpha chain of the interleukin-5
receptor (CD125). It was
developed by
MedImmune for the
treatment of asthma. Two
phase III
clinical trials of benralizumab...
-
director of the
board of Immunocore. She has
previously been
president at
MedImmune and AstraZeneca. She is a
council member of the Government–University–Industry...
